Mechanisms of echinocandin antifungal drug resistance

Annals of the New York Academy of Sciences

Volumn 1354, Issue 1, 2015, Pages 1-11

  Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Caspofungin; Chitin synthase; Echinocandin; FKS; Glucan synthase; Micafungin

Indexed keywords

ECHINOCANDIN; FKS PROTEIN; FUNGAL ENZYME; FUNGAL PROTEIN; GLUCAN SYNTHASE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; BETA GLUCAN; BETA-1,3-GLUCAN; GLUCOSYLTRANSFERASE;

ABDOMINAL INFECTION; ADAPTATION; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; BROTH DILUTION; CANDIDA GLABRATA; CELL STRESS; CELLULAR STRESS RESPONSE; DISEASE CARRIER; DRUG BIOAVAILABILITY; DRUG REEXPOSURE; ENVIRONMENTAL STRESS; ENZYME SUBUNIT; EPIDEMIOLOGY; FUNGAL CELL WALL; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; NONSENSE MUTATION; PROPHYLAXIS; ANTAGONISTS AND INHIBITORS; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROBIOLOGY; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES; HUMANS; SPECIES SPECIFICITY;

EID: 84945454920     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12831     Document Type: Article

References (133)

1. Brown, G.D. et al. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4: 165rv113.
2. Odds, F.C., A.J. Brown & N.A. Gow . 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11: 272-279.
3. Pappas, P.G. et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48: 503-535.
4. Cleveland, A.A. et al. 2012. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 55: 1352-1361.
5. Onishi, J. et al. 2000. Discovery of novel antifungal (1, 3)-beta-d-glucan synthase inhibitors. Antimicrob. Agents Chemother. 44: 368-377.
6. Turner, M.S., R.H. Drew & J.R. Perfect . 2006. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs. 11: 231-250.
7. Perlin, D.S. 2011. Current perspectives on echinocandin class drugs. Future Microbiol. 6: 441-457.
8. Barchiesi, F. et al. 2005. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49: 4989-4992.
9. Ernst, E.J. et al. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33: 75-80.
10. Bowman, J.C. et al. 2006. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans. Antimicrob. Agents Chemother. 50: 4202-4205.
11. Bowman, J.C. et al. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46: 3001-3012.
12. Pfaller, M.A. et al. 2003. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. 41: 5729-5731.
13. Bachmann, S.P., T.F. Patterson & J.L. Lopez-Ribot . 2002. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40: 2228-2230.
14. Niimi, K. et al. 2006. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob. Agents Chemother. 50: 1148-1155.
15. Bachmann, S.P. et al. 2003. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob. Agents Chemother. 47: 3657-3659.
16. Ferreira, J.A. et al. 2009. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob. Agents Chemother. 53: 4377-4384.
17. Kuhn, D.M. et al. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46: 1773-1780.
18. Simitsopoulou, M. et al. 2013. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob. Agents Chemother. 57: 2562-2570.
19. Chen, S.C., M.A. Slavin & T.C. Sorrell . 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71: 11-41.
20. Kofla, G. & M. Ruhnke . 2011. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur. J. Med. Res. 16: 159-166.
21. Odabasi, Z. et al. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51: 4214-4216.
22. Paderu, P. et al. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51: 2253-2256.
23. Wiederhold, N.P. et al. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51: 1616-1620.
24. Pfaller, M.A. et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48: 52-56.
25. Mazur, P. & W. Baginsky . 1996. In vitro activity of 1, 3-beta-d-glucan synthase requires the GTP-binding protein Rho1. J. Biol. Chem. 271: 14604-14609.
26. Mio, T. et al. 1997. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1, 3-glucan synthesis. J. Bacteriol. 179: 4096-4105.
27. Thompson, J.R. et al. 1999. A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181: 444-453.
28. Katiyar, S.K. et al. 2012. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: Implications for echinocandin resistance. Antimicrob. Agents Chemother. 56: 6304-6309.
29. Garcia-Effron, G. et al. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-beta-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53: 3690-3699.
30. Pfaller, M.A. et al. 2014. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob. Agents Chemother. 58: 916-922.
31. Pfaller, M.A. et al. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51: 2571-2581.
32. Arendrup, M.C. et al. 2013. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist. Updates 16: 81-95.
33. Pfaller, M.A. et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updates 14: 164-176.
34. Cleary, J.D. et al. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52: 2263-2265.
35. Garcia-Effron, G. et al. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54: 2225-2227.
36. Garcia-Effron, G., S. Park & D.S. Perlin . 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53: 112-122.
37. Kahn, J.N. et al. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51: 1876-1878.
38. Laverdiere, M. et al. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57: 705-708.
39. Miller, C.D. et al. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26: 877-880.
40. Garcia-Effron, G. et al. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52: 4181-4183.
41. Wiederhold, N.P. et al. 2008. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52: 4145-4148.
42. Pfeiffer, C.D. et al. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48: 2373-2380.
43. Thompson, G.R., 3rd et al. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52: 3783-3785.
44. Lewis, J.S., 2nd et al. 2013. Rapid emergence of Echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob. Agents Chemother. 57:4559-4561.
45. Dannaoui, E. et al. 2012. Candida spp. with acquired Echinocandin resistance, France, 2004-2010(1). Emerg. Infect. Dis. 18: 86-90.
46. Pfaller, M.A. et al. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69: 45-50.
47. Pfaller, M.A. et al. 2011. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int. J. Antimicrob. Agents 38: 65-69.
48. Pfaller, M.A. et al. 2011. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 49: 396-399.
49. Castanheira, M. et al. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54: 2655-2659.
50. Alexander, B.D. et al. 2013. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56: 1724-1732.
51. Pfaller, M.A. et al. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50: 1199-1203.
52. Farmakiotis, D., J.J. Tarrand & D.P. Kontoyiannis . 2014. Drug-resistant Candida glabrata infection in cancer patients. Emerg. Infect. Dis. 20: 1833-1840.
53. Lortholary, O. et al. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. Antimicrob. Agents Chemother. 55: 532-538.
54. Tortorano, A.M. et al. 2013. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 41: 655-662.
55. Fekkar, A. et al. 2013. Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob. Agents Chemother. 57: 2380-2382.
56. Pfaller, M.A. et al. 2012. Frequency of decreased susceptibility and resistance to Echinocandins among Fluconazole-resistant bloodstream isolates of Candida glabrata: results from the SENTRY Antimicrobial Surveillance Program (2006-2010) and the Centers for Disease Control and Prevention Population-Based Surveillance (2008-2010). J. Clin. Microbiol. 50: 1199-1203.
57. Eschenauer, G.A. et al. 2014. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob. Agents Chemother. 58: 1897-1906.
58. Arendrup, M.C. & D.S. Perlin . 2014. Echinocandin resistance: an emerging clinical problem? Curr. Opin. Infect. Dis. 27: 484-492.
59. Pham, C.D. et al. 2014. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob. Agents Chemother. 58: 4690-4696.
60. Perlin, D.S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updates 10: 121-130.
61. Katiyar, S., M. Pfaller & T. Edlind . 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50: 2892-2894.
62. Lackner, M. et al. 2014. Position and numbers of FKS mutations in C. albicans selectively influence in vitro and in vivo susceptibility to echinocandin treatment. Antimicrob. Agents Chemother. 58: 3626-3635.
63. Shields, R.K. et al. 2012. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56: 4862-4869.
64. Johnson, M.E., S.K. Katiyar & T.D. Edlind . 2011. A new Fks hotspot for acquired echinocandin resistance in yeast, and its contribution to intrinsic resistance of Scedosporium species. Antimicrob. Agents Chemother. 55: 3774-3781.
65. Katiyar, S.K. & T.D. Edlind . 2009. Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 53: 1772-1778.
66. Perlin, D.S. 2011. Echinocandin-resistant Candida: molecular methods and phenotypes. Curr. Fungal. Infect. Rep. 5: 113-119.
67. Arendrup, M.C. et al. 2012. Differential in vivo activity of Anidulafungin, Caspofungin and Micafungin against C. glabrata with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56: 2435-2442.
68. Howard, S.J. et al. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203: 1324-1332.
69. Slater, J.L. et al. 2011. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55: 3075-3083.
70. Wiederhold, N.P. et al. 2011. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob. Agents Chemother. 55: 3254-3260.
71. Castanheira, M. et al. 2014. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob. Agents Chemother. 58: 577-580.
72. Eng, W.K. et al. 1994. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. Gene 151: 61-71.
73. Jensen, R.H., H.K. Johansen & M.C. Arendrup . 2013. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob. Agents Chemother. 57: 614-617.
74. Pasquale, T. et al. 2008. Emergence of Candida tropicalis resistant to caspofungin. J. Antimicrob. Chemother. 61: 219.
75. Johnson, M.E. & T.D. Edlind . 2012. Topological and mutational analysis of Saccharomyces cerevisiae Fks1. Eukary. Cell 11: 952-960.
76. Pfaller, M.A. et al. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46: 150-156.
77. Mora-Duarte, J. et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347: 2020-2029.
78. Kale-Pradhan, P.B. et al. 2010. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis. Pharmacotherapy 30: 1207-1213.
79. Colombo, A.L. et al. 2003. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 22: 470-474.
80. Ghannoum, M.A. et al. 2009. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin. Microbiol. Infect. 15: 274-279.
81. Kabbara, N. et al. 2008. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 93: 639-640.
82. Forrest, G.N., E. Weekes & J.K. Johnson . 2008. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 56: 126-129.
83. Garcia-Effron, G. et al. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52: 2305-2312.
84. Johnson, M.E., S.K. Katiyar & T.D. Edlind . 2011. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob. Agents Chemother. 55: 3774-3781.
85. Ben-Ami, R. et al. 2011. The fitness and virulence cost of fks1 mutations causing echinocandin-resistance in Candida albicans. J. Infect. Dis. 204: 626-635.
86. d'Enfert, C. 2006. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr. Drug Targets 7: 465-470.
87. Mitchell, K.F. et al. 2013. Role of matrix beta-1, 3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob. Agents Chemother. 57: 1918-1920.
88. Desai, J.V. et al. 2013. Regulatory role of glycerol in Candida albicans biofilm formation. MBio 4: e00637-00612.
89. Walker, L.A., N.A. Gow & C.A. Munro . 2010. Fungal echinocandin resistance. Fungal Genet. Biol. 47: 117-126.
90. Reinoso-Martin, C. et al. 2003. The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukary. Cell 2: 1200-1210.
91. Levin, D.E. 2011. Regulation of cell wall biogenesis in Saccharomyces cerevisiae: the cell wall integrity signaling pathway. Genetics 189: 1145-1175.
92. + signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol. Microbiol. 63: 1399-1413.
93. Walker, L.A. et al. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4: e1000040.
94. LaFayette, S.L. et al. 2010. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog. 6: e1001069.
95. Singh, S.D. et al. 2009. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5: e1000532.
96. Shapiro, R.S. et al. 2012. The Hsp90 co-chaperone Sgt1 governs Candida albicans morphogenesis and drug resistance. PLoS One 7: e44734.
97. Singh-Babak, S.D. et al. 2012. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog. 8: e1002718.
98. Cowen, L.E. 2009. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog. 5: e1000471.
99. Cowen, L.E. & S. Lindquist . 2005. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
100. Lamoth, F. et al. 2014. Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus. J. Infect. Dis. 209: 473-481.
101. Cowen, L.E. et al. 2009. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. U.S.A. 106: 2818-2823.
102. Gow, N.A. et al. 2007. Immune recognition of Candida albicans beta-glucan by dectin-1. J. Infect. Dis. 196: 1565-1571.
103. Plaine, A. et al. 2008. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet. Biol. 45: 1404-1414.
104. Lee, K.K. et al. 2012. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob. Agents Chemother. 56: 208-217.
105. Walker, L.A., N.A. Gow & C.A. Munro . 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob. Agents Chemother. 57: 146-154.
106. Cota, J.M. et al. 2008. Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin. Antimicrob. Agents Chemother. 52: 1144-1146.
107. Stevens, D.A. et al. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1, 6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50: 3160-3161.
108. Clemons, K.V. et al. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50: 1293-1297.
109. Stevens, D.A., M. Espiritu & R. Parmar . 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48: 3407-3411.
110. Healey, K.R. et al. 2012. CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol. Microbiol. 86: 303-313.
111. Healey, K.R. et al. 2011. Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility. Antimicrob. Agents Chemother. 55: 3947-3949.
112. Reagan, D.R. et al. 1990. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J. Clin. Microbiol. 28: 2733-2738.
113. Harriott, M.M. & M.C. Noverr . 2011. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol. 19: 557-563.
114. Cheng, S. et al. 2014. Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. Infect. Immun. 82: 3015-3022.
115. Fekkar, A. et al. 2014. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur. J. Clin. Microbiol. Infect. Dis. 33: 1489-1496.
116. Beyda, N.D. et al. 2014. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin. Infect. Dis. 59: 819-825.
117. Blanchard, E. et al. 2011. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob. Agents Chemother. 55: 5358-5361.
118. Scott, L.J. 2012. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections. Drugs 72: 2141-2165.
119. Hope, W.W. et al. 2012. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin. Microbiol. Infect. 18(Suppl 7): 38-52.
120. dela Torre, P. & A.C. Reboli . 2014. Micafungin: an evidence-based review of its place in therapy. Core Evid. 9: 27-39.
121. van Burik, J.A. et al. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39: 1407-1416.
122. Chou, L.S. et al. 2007. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27: 1644-1650.
123. Mattiuzzi, G.N. et al. 2006. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother. 50: 143-147.
124. Doring, M. et al. 2012. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect. Dis. 12: 151.
125. Xu, S.X. et al. 2013. Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis. Transpl. Proc. 45: 407-414.
126. Ziakas, P.D., I.S. Kourbeti & E. Mylonakis . 2014. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin. Ther. 36: 292-306, e291.
127. Bizerra, F.C. et al. 2014. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob. Agents Chemother. 58: 2438-2440.
128. Ruggero, M.A. & J.E. Topal . 2014. Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy. Transpl. Infect. Dis. 16: 469-472.
129. Cowen, L.E. & W.J. Steinbach . 2008. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukary. Cell 7: 747-764.
130. Harrison, B.D. et al. 2014. A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biology 12: e1001815.
131. Galhardo, R.S., P.J. Hastings & S.M. Rosenberg . 2007. Mutation as a stress response and the regulation of evolvability. Crit. Rev. Biochem. Mol. Bio. 42: 399-435.
132. Chen, G. et al. 2012. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature 482: 246-250.
133. Sheltzer, J.M. et al. 2011. Aneuploidy drives genomic instability in yeast. Science 333: 1026-1030.